NCT01803594

Brief Summary

This study involves measuring subject's blood lipid responses after they consume a mixture of dietary fats of marine and dairy origin and vitamin supplements mixed into a milkshake, on three separate days. The investigators hope to learn more about how different food ingredients influence the metabolism HDL in individuals with low blood levels of HDL cholesterol.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
18

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Aug 2012

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2012

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 2, 2013

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

February 28, 2013

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 4, 2013

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

March 13, 2015

Completed
Last Updated

September 30, 2022

Status Verified

September 1, 2022

Enrollment Period

5 months

First QC Date

February 28, 2013

Last Update Submit

September 28, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Plasma lipoprotein profile

    Plasma lipoprotein size distribution and concentration will be measured by nuclear magnetic resonance (NMR)

    0, 2, 4 hour postprandial

Secondary Outcomes (3)

  • Plasma HDL proteome

    0, 2, 4 hours postprandial

  • Urinary metabolomics

    0, 2, 4 hours

  • Red blood cell functionality

    0, 2, 4 hours postprandially

Study Arms (3)

Control Shake

PLACEBO COMPARATOR

Each shake delivers 30% of each participant's calculated energy expenditure and provides 45% energy as fat, 40% energy as carbohydrate and 15% energy as protein. The shake contains whipping cream, frozen fruit, glucose polymer, and protein powder.

Other: Control

PC700, Krill Oil, and Lutein

ACTIVE COMPARATOR

Each shake delivers 30% of each participant's calculated energy expenditure and provides 45% energy as fat, 40% energy as carbohydrate and 15% energy as protein. The shake contains whipping cream, frozen fruit, glucose polymer, and protein powder. Fifty percent of the fat is made up of PC700. Additionally, 3.0g Krill oil and 40mg of lutein capsules are swallowed with water. Neptune Krill Oil capsules (Nutrigold); Lutein capsules (Jarrow Formulas); PC700 = dairy lipids (Fonterra brand)

Dietary Supplement: Krill OilDietary Supplement: LuteinDietary Supplement: Dairy phospholipids

PC700, Krill Oil, Lutein, and Niacin

ACTIVE COMPARATOR

Each shake delivers 30% of each participant's calculated energy expenditure and provides 45% energy as fat, 40% energy as carbohydrate and 15% energy as protein. The shake contains whipping cream, frozen fruit, glucose polymer, and protein powder. Fifty percent of the fat is made up of PC700. Additionally, 3.0g Krill oil and 40mg of lutein capsules are swallowed with water. Nicotinic acid was added to each shake prior to consumption at a doses 5mg/kg of body weight. Neptune Krill Oil capsules (Nutrigold); Lutein capsules (Jarrow Formulas); PC700 (Fonterra); Nicotinic acid (Natures Way)

Dietary Supplement: Krill OilDietary Supplement: LuteinDietary Supplement: Nicotinic acidDietary Supplement: Dairy phospholipids

Interventions

Krill OilDIETARY_SUPPLEMENT

Neptune Krill Oil Gold

PC700, Krill Oil, Lutein, and NiacinPC700, Krill Oil, and Lutein
LuteinDIETARY_SUPPLEMENT

Jarrow Formulas

PC700, Krill Oil, Lutein, and NiacinPC700, Krill Oil, and Lutein
Nicotinic acidDIETARY_SUPPLEMENT

Natures Way

PC700, Krill Oil, Lutein, and Niacin
Dairy phospholipidsDIETARY_SUPPLEMENT

PC700 manufactured by Fonterra

PC700, Krill Oil, Lutein, and NiacinPC700, Krill Oil, and Lutein
ControlOTHER

Control shake without dietary supplements

Control Shake

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18-65 years
  • Plasma HDL cholesterol (Less than 50 mg/dL)

You may not qualify if:

  • History of gastrointestinal disorders like Crohns disease, colitis, irritable bowel syndrome
  • History of cardiovascular events: stroke, heart attack, cardiac arrhythmia
  • History of peptic ulcers, gastritis
  • History of gout
  • History of being under care of any psychiatric conditions (schizophrenia and depression associated with response to niacin)
  • Cancer
  • Type 1 or 2 diabetes
  • Known presence of significant metabolic disease which could impact results of study (hepatic, renal disease)
  • Low blood pressure (defined as 3 consecutive readings below 100/60 mmHg at screening)
  • Self report skin sensitivities; self report to rash easily
  • Self report to hot flashes currently experience due to menopause
  • Hypersensitivity to niacin
  • Muscle disorders such as myasthenia gravis
  • Pending surgery within the next 3 months
  • Known allergy to study food (shellfish, fish, nut, soy)
  • +11 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UC Davis, Ragle Human Nutrition Center

Davis, California, 95616, United States

Location

Related Publications (7)

  • Dalbeth N, Gracey E, Pool B, Callon K, McQueen FM, Cornish J, MacGibbon A, Palmano K. Identification of dairy fractions with anti-inflammatory properties in models of acute gout. Ann Rheum Dis. 2010 Apr;69(4):766-9. doi: 10.1136/ard.2009.113290. Epub 2009 Aug 26.

    PMID: 19713204BACKGROUND
  • Snow DR, Ward RE, Olsen A, Jimenez-Flores R, Hintze KJ. Membrane-rich milk fat diet provides protection against gastrointestinal leakiness in mice treated with lipopolysaccharide. J Dairy Sci. 2011 May;94(5):2201-12. doi: 10.3168/jds.2010-3886.

    PMID: 21524510BACKGROUND
  • Mozaffarian D, Rimm EB, Herrington DM. Dietary fats, carbohydrate, and progression of coronary atherosclerosis in postmenopausal women. Am J Clin Nutr. 2004 Nov;80(5):1175-84. doi: 10.1093/ajcn/80.5.1175.

    PMID: 15531663BACKGROUND
  • Tholstrup T, Vessby B, Sandstrom B. Difference in effect of myristic and stearic acid on plasma HDL cholesterol within 24 h in young men. Eur J Clin Nutr. 2003 Jun;57(6):735-42. doi: 10.1038/sj.ejcn.1601605.

    PMID: 12792657BACKGROUND
  • Bunea R, El Farrah K, Deutsch L. Evaluation of the effects of Neptune Krill Oil on the clinical course of hyperlipidemia. Altern Med Rev. 2004 Dec;9(4):420-8.

    PMID: 15656713BACKGROUND
  • Ribaya-Mercado JD, Blumberg JB. Lutein and zeaxanthin and their potential roles in disease prevention. J Am Coll Nutr. 2004 Dec;23(6 Suppl):567S-587S. doi: 10.1080/07315724.2004.10719427.

    PMID: 15640510BACKGROUND
  • Kiokias S, Gordon MH. Dietary supplementation with a natural carotenoid mixture decreases oxidative stress. Eur J Clin Nutr. 2003 Sep;57(9):1135-40. doi: 10.1038/sj.ejcn.1601655.

    PMID: 12947433BACKGROUND

Related Links

MeSH Terms

Conditions

Dyslipidemias

Interventions

LuteinNiacin

Condition Hierarchy (Ancestors)

Lipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

XanthophyllsCarotenoidsPolyenesAlkenesHydrocarbons, AcyclicHydrocarbonsOrganic ChemicalsCyclohexenesCyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicTerpenesPigments, BiologicalBiological FactorsNicotinic AcidsAcids, HeterocyclicHeterocyclic CompoundsPyridinesHeterocyclic Compounds, 1-Ring

Study Officials

  • Jennifer T Smilowitz, PhD

    University of California, Davis

    PRINCIPAL INVESTIGATOR
  • J. Bruce German, PhD

    University of California, Davis

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 28, 2013

First Posted

March 4, 2013

Study Start

August 1, 2012

Primary Completion

January 2, 2013

Study Completion

March 13, 2015

Last Updated

September 30, 2022

Record last verified: 2022-09

Locations